Has Bashar Saour, MD received payments from drug or device companies?

Yes. Drug and device makers reported $605 in general payments to Bashar Saour, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bashar Saour, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bashar Saour, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bashar Saour, MD

Neurology · Toledo, OHNPI 1164872958

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 26.1% of the total. Reporting peaked in 2024 at $255 and has fallen 50.1% since, to $127 in 2025. That places this record below the midpoint for neurology clinicians in OH, where the typical reported total is $970.

$605in general payments, 2019–2025

Across 27 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acadia Pharmaceuticals Inc$158
UCB, Inc.$155
Akcea Therapeutics, Inc.$87
SK Life Science, Inc.$35
Neurelis, Inc.$34
Pfizer$29
plus $107 from 7 others

$12,540in research payments, 2019–2025

Across 4 payments — averaging $3134.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$13K

What the payments were for

Food & beverage$605100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acadia Pharmaceuticals Inc	3	$158
UCB, Inc.	10	$155
Akcea Therapeutics, Inc.	1	$87
SK Life Science, Inc.	2	$35
Neurelis, Inc.	2	$34
Pfizer	2	$29
Genentech USA, Inc.	1	$24
Merz Pharmaceuticals, LLC	1	$16
Amneal Pharmaceuticals LLC	1	$15
Amylyx Pharmaceuticals, Inc.	1	$14
Otsuka America Pharmaceutical, Inc.	1	$13
Biogen	1	$13
Teva Pharmaceuticals USA, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAYBUE$131

How this compares

$605 in reported general payments places this provider in the 40th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio →

Medicare billing

Part B allowed, 2024

$70,189

Medicare patients

440

Services billed

784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a	14	$113,866
Gabapentin	87	$1,705
Baclofen	20	$1,432
Duloxetine Hcl	57	$1,102
Primidone	18	$910
Pregabalin	55	$792
Topiramate	61	$525
Levetiracetam	18	$388
Amitriptyline Hcl	47	$313
Fluoxetine Hcl	13	$125
Donepezil Hcl	15	$112
Memantine Hcl	11	$86
Sertraline Hcl	14	$74
Tizanidine Hcl	21	$61
Cyclobenzaprine Hcl	17	$46

Paid to pharmacies, not to this prescriber.

Other neurology in Toledo

Lawrence ElmerToledo$687K
Faizan HafeezToledo$337K
Howard SchechtToledo$183K
Aram ZabetiCincinnati$1.6M
Kenneth MankowskiColumbus$1.4M
Aaron BosterColumbus$1.2M
Martin TaylorNew Albany$821K
Jacqueline NicholasColumbus$743K
Kenneth PugarCenterville$582K
Brendan BauerSheffield Village$548K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →